Last updated: 2026-09-16 09:45:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Trevi Therapeutics, Inc. (TRVI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $15,08, with a market capitalisation of $2,26B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7,92 to $20,22. This page covers its latest market performance, valuation, price trends and company information.
$2,26B | |
$15,05 | |
$20,22 | |
$0,46 | |
$15,04 | |
1,18K | |
2,20M | |
-- | |
$20,22 | |
$7,92 | |
-- | |
-- |
Trevi Therapeutics, Inc. (TRVI) is trading at $15,08 in pre-market trading as of 2026-09-16 09:30:00, up 0,23% ($0,04) from the previous close of $15,04
Pre-market trading shows how investors are pricing TRVI before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Trevi Therapeutics, Inc. (TRVI) moved from $17,26 to $15,08, representing a decline of 12,66% ($2,19).
The stock traded between $14,78 and $17,32 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,46 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 58,2%
TRVI is currently trading at $15,08, placing it 58,2% of the way from its 52-week low of $7,92 to its 52-week high of $20,22. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 34 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Trevi Therapeutics, Inc. (TRVI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.